HDACs and HDAC Inhibitors in Cancer Development and Therapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cold Spring Harbor Perspectives in Medicine

• Publication date

  2016-10-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1101/cshperspect.a026831PMID 27599530PMCID PMC5046688
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Histone Deacetylase Inhibitors Resensitize EGFR/EGFRvIII-Overexpressing, Erlotinib-Resistant Glioblastoma Cells to Tyrosine Kinase Inhibition

  2016cited by this paper
• Resminostat: Opening the door to epigenetic treatments for liver cancer

  2016cited by this paper
• Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents

  2016cited by this paper
• Downregulation of HDAC6 promotes angiogenesis in hepatocellular carcinoma cells and predicts poor prognosis in liver transplantation patients

  2016cited by this paper
• Phase I trial of valproic acid and lenalidomide in patients with advanced cancer

  2015cited by this paper
• Selective inhibition of HDAC8 decreases neuroblastoma growth in vitro and in vivo and enhances retinoic acid-mediated differentiation

  2015cited by this paper
• Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.

  2015cited by this paper
• Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization

  2015cited by this paper
• Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma

  2015cited by this paper
• HDAC Family Members Intertwined in the Regulation of Autophagy: A Druggable Vulnerability in Aggressive Tumor Entities

  2015cited by this paper
• Synthesis and biological evaluation of novel histone deacetylases inhibitors with nitric oxide releasing activity.

  2015cited by this paper
• AMPK-HDAC5 pathway facilitates nuclear accumulation of HIF-1α and functional activation of HIF-1 by deacetylating Hsp70 in the cytosol

  2015cited by this paper
• Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors

  2015cited by this paper
• Histone Deacetylase 10 Regulates DNA Mismatch Repair and May Involve the Deacetylation of MutS Homolog 2*

  2015cited by this paper
• Histone deacetylase inhibitors in hematological malignancies and solid tumors

  2015cited by this paper
• Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma

  2015cited by this paper
• Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer

  2015cited by this paper
• Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

  2015cited by this paper
• Class IIa HDAC inhibition enhances ER stress-mediated cell death in multiple myeloma

  2015cited by this paper
• Histone deacetylase 6 promotes growth of glioblastoma through inhibition of SMAD2 signaling

  2015cited by this paper
• HIPK2 restricts SIRT1 activity upon severe DNA damage by a phosphorylation-controlled mechanism

  2015cited by this paper
• Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.

  2015cited by this paper
• ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat

  2015cited by this paper
• Deacetylation of nuclear LC3 drives autophagy initiation under starvation.

  2015cited by this paper
• Emerging approaches for histone deacetylase inhibitor drug discovery

  2015cited by this paper
• Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors

  2015cited by this paper
• Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model

  2015cited by this paper
• HDAC8, A Potential Therapeutic Target for the Treatment of Malignant Peripheral Nerve Sheath Tumors (MPNST)

  2015cited by this paper
• Histone Deacetylase 10 Regulates the Cell Cycle G2/M Phase Transition via a Novel Let-7–HMGA2–Cyclin A2 Pathway

  2015cited by this paper
• Ubiquitinated Sirtuin 1 (SIRT1) Function Is Modulated during DNA Damage-induced Cell Death and Survival*

  2015cited by this paper
• Cells adapt to the epigenomic disruption caused by histone deacetylase inhibitors through a coordinated, chromatin-mediated transcriptional response

  2015cited by this paper
• Design and structure activity relationship of tumor-homing histone deacetylase inhibitors conjugated to folic and pteroic acids.

  2015cited by this paper
• Autophagy in cancer

  2015cited by this paper
• Acetylation site specificities of lysine deacetylase inhibitors in human cells

  2015cited by this paper
• A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

  2015cited by this paper
• Cucurbitacin B Alters the Expression of Tumor-Related Genes by Epigenetic Modifications in NSCLC and Inhibits NNK-Induced Lung Tumorigenesis

  2015cited by this paper
• Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma

  2015cited by this paper
• Ricolinostat (ACY‐1215) induced inhibition of aggresome formation accelerates carfilzomib‐induced multiple myeloma cell death

  2015cited by this paper
• Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

  2015cited by this paper
• Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma

  2015cited by this paper
• Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach

  2015cited by this paper
• Induction of apoptosis and autophagy via sirtuin1- and PI3K/Akt/mTOR-mediated pathways by plumbagin in human prostate cancer cells

  2015cited by this paper
• Apicidin inhibits cell growth by downregulating IGF-1R in salivary mucoepidermoid carcinoma cells.

  2015cited by this paper
• Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression

  2015cited by this paper
• HDAC inhibitors still need a home run, despite recent approval

  2015cited by this paper
• Novel Bioactive Hybrid Compound Dual Targeting Estrogen Receptor and Histone Deacetylase for the Treatment of Breast Cancer.

  2015cited by this paper
• MPP8 and SIRT1 crosstalk in E‐cadherin gene silencing and epithelial–mesenchymal transition

  2015cited by this paper
• Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia

  2015cited by this paper
• Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine

  2015cited by this paper
• KAP1 Deacetylation by SIRT1 Promotes Non-Homologous End-Joining Repair

  2015cited by this paper
• MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1.

  2015cited by this paper
• Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

  2015cited by this paper
• SIRT1 Positively Regulates Autophagy and Mitochondria Function in Embryonic Stem Cells Under Oxidative Stress

  2014cited by this paper
• Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast

  2014cited by this paper
• Inhibition of histone deacetylase 4 increases cytotoxicity of docetaxel in gastric cancer cells

  2014cited by this paper
• Histone deacetylase inhibitors and cell death

  2014cited by this paper
• Harnessing the p53-PUMA Axis to Overcome DNA Damage Resistance in Renal Cell Carcinoma

  2014cited by this paper
• Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells

  2014cited by this paper
• HDAC6 deacetylates and ubiquitinates MSH2 to maintain proper levels of MutSα.

  2014cited by this paper
• Synergistic enhancement of NK cell-mediated cytotoxicity by combination of histone deacetylase inhibitor and ionizing radiation

  2014cited by this paper
• Decreased expression of histone deacetylase 10 predicts poor prognosis of gastric cancer patients.

  2014cited by this paper
• Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators

  2014cited by this paper
• Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma

  2014cited by this paper
• Erasers of histone acetylation: the histone deacetylase enzymes.

  2014cited by this paper
• Trichostatin A, a histone deacetylase inhibitor, suppresses proliferation and epithelial–mesenchymal transition in retinal pigment epithelium cells

  2014cited by this paper
• Interferon-stimulated Gene 15 (ISG15) and ISG15-linked Proteins Can Associate with Members of the Selective Autophagic Process, Histone Deacetylase 6 (HDAC6) and SQSTM1/p62*

  2014cited by this paper
• Histone Deacetylase Inhibitor Sensitizes Apoptosis-Resistant Melanomas to Cytotoxic Human T Lymphocytes through Regulation of TRAIL/DR5 Pathway

  2014cited by this paper
• Design, Synthesis, and Biological Activity of NCC149 Derivatives as Histone Deacetylase 8‐Selective Inhibitors

  2014cited by this paper
• mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells

  2014cited by this paper
• Role of SIRT1 in regulation of epithelial-to-mesenchymal transition in oral squamous cell carcinoma metastasis

  2014cited by this paper
• Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.

  2014cited by this paper
• Autophagy Induction by SIRT6 through Attenuation of Insulin-like Growth Factor Signaling Is Involved in the Regulation of Human Bronchial Epithelial Cell Senescence

  2014cited by this paper
• HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts

  2014cited by this paper
• Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest

  2014cited by this paper
• Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia

  2014cited by this paper
• Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications

  2014cited by this paper
• Histone deacetylase 3 as a novel therapeutic target in multiple myeloma

  2014cited by this paper
• HDAC5 promotes cell proliferation in human hepatocellular carcinoma by up-regulating Six1 expression.

  2014cited by this paper
• Statins inhibit tumor progression via an enhancer of zeste homolog 2-mediated epigenetic alteration in colorectal cancer

  2014cited by this paper
• Histone Deacetylases

  2014cited by this paper
• Combination of proteasome and class I HDAC inhibitors induces apoptosis of NPC cells through an HDAC6‐independent ER stress‐induced mechanism

  2014cited by this paper
• SIRT1 Deacetylates TopBP1 and Modulates Intra-S-Phase Checkpoint and DNA Replication Origin Firing

  2014cited by this paper
• Belinostat for the treatment of peripheral T-cell lymphomas.

  2014cited by this paper
• Downregulation of Ca2+-Activated Cl− Channel TMEM16A by the Inhibition of Histone Deacetylase in TMEM16A-Expressing Cancer Cells

  2014cited by this paper
• Expression of histone deacetylases 1, 2 and 3 in urothelial bladder cancer

  2014cited by this paper
• Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells.

  2014cited by this paper
• Improved synthesis and structural reassignment of MC1568: a class IIa selective HDAC inhibitor.

  2014cited by this paper
• Azaindolylsulfonamides, with a more selective inhibitory effect on histone deacetylase 6 activity, exhibit antitumor activity in colorectal cancer HCT116 cells.

  2014cited by this paper
• HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A

  2014cited by this paper
• Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells

  2014cited by this paper
• New and emerging HDAC inhibitors for cancer treatment.

  2014cited by this paper
• Vorinostat as a radiosensitizer for brain metastasis: a phase I clinical trial

  2014cited by this paper
• The anticancer effects of HDAC inhibitors require the immune system

  2014cited by this paper
• Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance

  2014cited by this paper
• BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts

  2014cited by this paper
• Further Characterization of HDAC and SIRT Gene Expression Patterns in Pancreatic Cancer and Their Relation to Disease Outcome

  2014cited by this paper
• Phase I First-in-Human Study of CUDC-101, a Multitargeted Inhibitor of HDACs, EGFR, and HER2 in Patients with Advanced Solid Tumors

  2014cited by this paper
• Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders

  2014cited by this paper
• HDAC8 and STAT3 repress BMF gene activity in colon cancer cells

  2014cited by this paper
• Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group.

  2013cited by this paper

• HDAC11 Regulates RNA Splicing via De-Fatty Acylation of SF3B2

  2026cites this paper
• Rational design of dual ALK inhibitors: scaffolds and strategies to circumvent drug resistance

  2026cites this paper
• Asiatic acid promotes CD8+ T cell-mediated antitumor immunity by targeting HDAC8/CXCL10 axis in hepatocellular carcinoma.

  2026cites this paper
• Oncolytic viruses: advanced strategies in cancer therapy

  2026cites this paper
• Targeting the NAT10-HDAC4 positive feedback loop counteracts immunosuppression in breast cancer

  2026cites this paper
• Drug screening on tumor organoids exposes therapeutic vulnerabilities of meningiomas to HDAC1/2i panobinostat.

  2026cites this paper
• Discovery of Potent HDAC6-Selective Inhibitors Based on Artemisinin: Design, Synthesis, and Antitumor Evaluation.

  2026cites this paper
• Epigenetic modulation to overcome immune suppression in pancreatic cancer.

  2026cites this paper
• Impact of Arsenite on Transient and Persistent Histone H3 Modifications and Transcriptional Response

  2026cites this paper
• PRDX6 Modulates Immune Checkpoint Inhibitor Response by Antagonizing Ferroptosis Induced By HDAC Inhibitors

  2026cites this paper
• HDAC4 overexpression predicts aggressive phenotypes and poor outcomes in urothelial carcinoma

  2026cites this paper
• HOXD10 expression in oral cancer is driven by histone acetylation rather than promoter DNA methylation.

  2026cites this paper
• Structures, characteristics, and anticancer mechanisms of taxanes, beta-glucans, and isothiocyanates

  2026cites this paper
• Panobinostat Potentiates the Antitumor Efficacy of 5-Fluorouracil in Gastric Cancer by Suppressing Thymidylate Synthase Expression

  2026cites this paper
• Cathepsin B Mediates HDAC Inhibitor-Induced Epithelial-Mesenchymal Transition in Lung Cancer Cells.

  2026cites this paper
• Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function.

  2026cites this paper
• Treatment of pulmonary fibrosis: From disease mechanisms to future novel therapies (Review).

  2026cites this paper
• The Histone-Modified Landscape: Core Mechanisms of Osimertinib Resistance in EGFR-Mutant Lung Cancer.

  2026cites this paper
• Biology of Brain Metastases.

  2026cites this paper
• Integrated QSAR, molecular docking, and dynamics-based discovery of a potent selective HDAC1 inhibitor with therapeutic potential in aggressive cancers.

  2026cites this paper
• Disruption of zinc homeostasis reduces histone acetylation levels in normal and tumor cells

  2026cites this paper
• Epigenetic Inhibition of HDAC7 by Daidzein isolated from Macrotyloma uniflorum: A potential therapeutic approach in leukemia in silico, in-vitro and in-vivo

  2026cites this paper
• Construction and validation of acetylation-related gene signatures for immune landscape analysis and prognostication risk prediction in luminal breast cancer

  2025cites this paper
• Design, synthesis, and antitumor activity study of β-carboline derivatives as selective HDAC1/2 inhibitors.

  2025cites this paper
• New insights into coordinated regulation of AHR promoter transcription; molecular mechanisms and therapeutic targets

  2025cites this paper
• Curcumin Derivative CU4c Exhibits HDAC-Inhibitory and Anticancer Activities Against Human Lung Cancer Cells In Vitro and in Mouse Xenograft Models

  2025cites this paper
• Chemical perturbations impacting histone acetylation govern colorectal cancer differentiation.

  2025cites this paper
• Contribution of Prostaglandin E2‐Induced Neuronal Excitation to Drug Resistance in Glioblastoma Countered by a Novel Blood–Brain Barrier Crossing Celecoxib Derivative

  2025cites this paper
• Current Advances and Future Directions for Sensitizing Gastric Cancer to Immune Checkpoint Inhibitors

  2025cites this paper
• PHF20L1: An Epigenetic Regulator in Cancer and Beyond

  2025cites this paper
• A Novel HDAC6 Inhibitor Enhances the Efficacy of Paclitaxel Against Ovarian Cancer Cells

  2025cites this paper
• Inhibitory Effect of Novel Dihydroxamate Derivatives for Histone Deacetylase 1.

  2025cites this paper
• From Genomics to AI: Revolutionizing Precision Medicine in Oncology

  2025cites this paper
• The anticancer effect of the HDAC inhibitor belinostat is enhanced by inhibitors of Bcl‐xL or Mcl‐1 in ovarian cancer

  2025cites this paper
• Valproic acid exposure alters histone deacetylase mRNA expression profile in oral cancer and premalignant cell lines

  2025cites this paper
• First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study

  2025cites this paper
• Repurposing Nirmatrelvir for Hepatocellular Carcinoma: Network Pharmacology and Molecular Dynamics Simulations Identify HDAC3 as a Key Molecular Target

  2025influential citation
• Design, synthesis and evaluation of structural optimization derived HDAC6 isoform-selective inhibitor.

  2025cites this paper
• Effect of SLC5A8 Missense Variants on Its Tumor-Suppressive Function

  2025cites this paper
• Transcriptional remodeling shapes therapeutic vulnerability to necroptosis in acute lymphoblastic leukemia

  2025cites this paper
• HDAC1 acts as a tumor suppressor in ALK-positive anaplastic large cell lymphoma: implications for HDAC inhibitor therapy

  2025cites this paper
• Functions and mechanisms of non-histone post-translational modifications in cancer progression

  2025cites this paper
• Regulatory mechanism of ABCB1 transcriptional repression by HDAC5 in rat hepatocytes under hypoxic environment

  2025cites this paper
• HDAC5, an early osimertinib-responsive gene, is a novel therapeutic target for the drug resistance in EGFR-mutant lung adenocarcinoma cells

  2025cites this paper
• HDAC3 inhibition mitigates acute kidney injury by alleviating RIPK1-mediated programmed necrosis

  2025cites this paper
• The gut microbiome and cancer: from tumorigenesis to therapy

  2025cites this paper
• HDAC6 facilitates LUAD progression by inducing EMT and enhancing macrophage polarization towards the M2 phenotype

  2025cites this paper
• Histone deacetylase inhibitors sensitize glioblastoma models to temozolomide and reprogram immunosuppressive myeloid cells

  2025cites this paper
• Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo

  2025cites this paper
• Comprehensive multi-omics analysis of histone acetylation modulators identifies ASH1L as a novel aggressive marker for osteosarcoma

  2025cites this paper
• ARID1A deficiency promotes malignant proliferation of hepatocellular carcinoma by activating HDAC7/ENO1 signaling pathway

  2025cites this paper
• A comprehensive review on the antitumor mechanisms of polysaccharides and their structure-activity relationships-Current insights and future directions.

  2025cites this paper
• Acetylation-Mediated Epigenetic Consequences for Biological Control and Cancer.

  2025cites this paper
• Histone and Non-histone Reversible Acetylation in Development, Aging, and Disease.

  2025cites this paper
• Colon cancer cells evade drug action by enhancing drug metabolism

  2025cites this paper
• Epigenetic Therapeutics: Reprogramming Triple-Negative Breast Cancer into Responsive Subtypes.

  2025cites this paper
• GPM6B inhibits tumor progression by targeting HPGD in lung adenocarcinoma

  2025cites this paper
• Clinical progress and functional modalities of HDAC inhibitor-based combination therapies in cancer treatment

  2025influential citation
• Histone deacetylases 10 as a prognostic biomarker correlates with tumor microenvironment and therapy response in colorectal cancer

  2025cites this paper
• Targeting epigenetic regulators as a promising avenue to overcome cancer therapy resistance

  2025cites this paper
• Epigenetic alterations in prostate cancer: the role of chromatin remodeling.

  2025cites this paper
• Contribution of reversible histone acetylation to freeze tolerance and recovery in wood frog kidneys

  2025cites this paper
• Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor Microenvironment

  2025cites this paper
• Integrated transcriptome analysis and combinatorial machine learning to construct a homeostatic model of acetylation for ccRCC and validate the key gene GCNT4

  2025cites this paper
• Trichostatin A augments cell migration and epithelial-mesenchymal transition in esophageal squamous cell carcinoma through BRD4/c-Myc endoplasmic reticulum-stress pathway

  2025cites this paper
• Protein lactylation in cancer: mechanisms and potential therapeutic implications

  2025cites this paper
• Hybrid histone deacetylase-kinase inhibitor potentiates venetoclax-induced cell death in chronic lymphocytic leukemia

  2025cites this paper
• Identification of Potential Histone deacetylase 3 Inhibitors from Fermented Bamboo Shoots using GC-MS Metabolomics, Molecular Docking, Pharmacokinetics and Molecular Dynamics Simulations Approaches

  2025cites this paper
• Computationally Guided Design, Synthesis, and Evaluation of Novel Non-Hydroxamic Histone Deacetylase Inhibitors, Based on N-Trifluoroacetamide as a Zinc-Binding Group, Against Breast Cancer

  2025cites this paper
• Wound Healing Effect of HDACi Repositioned Molecules in the Therapy for Chronic Wounds Models

  2025cites this paper
• Histone modification inhibitors: An emerging frontier in thyroid Cancer therapy.

  2025cites this paper
• HDAC3: A Multifaceted Modulator in Immunotherapy Sensitization

  2025cites this paper
• Comparison of Anticancer Effects of Histone Deacetylase Inhibitors CG-745 and Suberoylanilide Hydroxamic Acid in Non-small Cell Lung Cancer

  2025cites this paper
• The histone deacetylase inhibitor Scriptaid targets G-quadruplexes

  2025cites this paper
• A narrative review of epigenetic marker in H3K27ac and its emerging potential as a therapeutic target in cancer.

  2025cites this paper
• Epigenetic modifications in early stage lung cancer: pathogenesis, biomarkers, and early diagnosis

  2025cites this paper
• Epigenetic drugs in cancer therapy

  2025cites this paper
• Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors

  2025cites this paper
• Histone crotonylation in tumors (Review)

  2025cites this paper
• Discovery of novel selective HDAC6 inhibitors via a scaffold hopping approach for the treatment of idiopathic pulmonary fibrosis (IPF) in vitro and in vivo.

  2025cites this paper
• MS275 induces tumor immunosuppression by upregulating PD-L1 and enhances the efficacy of anti-PD-1 immunotherapy in colorectal cancer

  2025cites this paper
• The influence of the microbiome on radiotherapy and DNA damage responses

  2025cites this paper
• New and Effective Inhibitor of Class I HDACs, Eimbinostat, Reduces the Growth of Hematologic Cancer Cells and Triggers Apoptosis

  2025cites this paper
• The Warburg effect: the hacked mitochondrial-nuclear communication in cancer.

  2025cites this paper
• Histone acetylation modulators in breast cancer

  2025cites this paper
• Pan-HDAC inhibitor LAQ824 inhibits the progression of pancreatic ductal adenocarcinoma and suppresses immune escape by promoting antigen presentation.

  2025cites this paper
• Enhancing venetoclax efficacy in leukemia through association with HDAC inhibitors

  2025cites this paper
• Inhibition of Hepatoblastoma by Ganoderma Lucidum Polysaccharide via the Induction of HDAC4‐p16‐RB Axis‐Mediated Cellular Senescence

  2025cites this paper
• Histone modifications in the regulation of erythropoiesis

  2025cites this paper
• Multifaceted landscape of the StAR protein in steroid biosynthesis: from development to degeneration.

  2025cites this paper
• Development of potent and selective tetrahydro-β-carboline-based HDAC6 inhibitors with promising activity against triple-negative breast cancer.

  2025cites this paper
• The inhibitory and anti-inflammatory effects of TMP269 on peste des petits ruminants virus replication

  2025cites this paper
• Elevated HDAC4 Expression Is Associated with Reduced T-Cell Inflamed Tumor Microenvironment Gene Signatures and Immune Checkpoint Inhibitor Effectiveness in Melanoma

  2025cites this paper
• Progression and expansion of ALK inhibitors against NSCLC: A dual target approach.

  2025cites this paper
• Proteomic analysis reveals modulation of key proteins in follicular thyroid cancer progression.

  2025cites this paper
• Skimmianine Modulates Tumor Proliferation and Immune Dynamics in Breast Cancer by Targeting PCNA and TNF-α

  2025cites this paper
• Synergistic Integration of HDAC Inhibitors and Individualized Neoantigen Therapy (INT): A Next-Generation Combinatorial Approach for Cancer Immunotherapy

  2025cites this paper
• The study of Histone Deacetylases Immunoexpression in relation to Regulating Vascular Endothelial Growth Factor (VEGF) Implicated in Malignant Progression of Colorectal cancer

  2025cites this paper
• Amide linked chalcone derivatives, a promising class of compounds with versatile biological effects

  2025cites this paper
• Histone Deacetylase Inhibitor Largazole Deactivates A Subset of Superenchancers and Causes Mitotic Chromosome Mis-alignment by Suppressing SP1 and BRD4

  2025cites this paper